NASDAQ: CLDXCelldex Therapeutics Inc Stock
$38.37+1.59 (+4.32%)
Updated Jul 2, 2026
CLDX Price
$38.37
Fair Value Price
$0.04
Market Cap
$3.01B
52 Week Low
$19.72
52 Week High
$39.16
P/E
-8.99x
P/B
6.6x
P/S
2,438.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$866.00k
Earnings
-$283.65M
Gross Margin
100%
Operating Margin
-32,753.58%
Profit Margin
-32,753.6%
Debt to Equity
0.12
Operating Cash Flow
-$222M
Beta
1.29
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CLDX Overview
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLDX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CLDX
Ranked#423 of 463
Ranked#423 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important CLDX news, forecast changes, insider trades & much more!
CLDX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLDX ($38.37) is overvalued by 99,427.86% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CLDX ($38.37) is not significantly undervalued (99,427.86%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLDX due diligence checks available for Premium users.
Valuation
CLDX fair value
Fair Value of CLDX stock based on Discounted Cash Flow (DCF)
Price
$38.37
Fair Value
$0.04
Overvalued by
99,427.86%
CLDX ($38.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLDX ($38.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.99x
Industry
17.59x
Market
8.54x
CLDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.6x
Industry
5.6x
CLDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLDX's financial health
Profit margin
Revenue
$15.0k
Net Income
-$78.7M
Profit Margin
-524,566.7%
CLDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$511.3M
Liabilities
$55.0M
Debt to equity
0.12
CLDX's short-term assets ($459.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLDX's short-term assets ($459.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$65.6M
Investing
$72.1M
Financing
$327.0k
CLDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLDX vs Biotech Stocks
Celldex Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.